Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

November 30, 2010

Conditions
Breast NeoplasmsBreast Cancer
Interventions
DRUG

Vinflunine

Novel second generation vinca alkaloid

DRUG

Trastuzumab

Anti-HER2 monoclonal antibody

Trial Locations (10)

29303

Spartanburg Regional Medical Center, Spartanburg

30501

Northeast Georgia Medical Center, Gainesville

32256

Integrated Community Oncology Network, Jacksonville

33805

Watson Clinic Center for Cancer Care and Research, Lakeland

33901

Florida Cancer Specialists, Fort Myers

36207

Northeast Alabama Regional Medical Center, Anniston

37205

Tennessee Oncology, Nashville

37404

Associates in Hematology Oncology, Chattanooga

49503

Grand Rapids Clinical Oncology Program, Grand Rapids

71301

Hematology Oncology Life Center, Alexandria

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER